Show simple item record

dc.contributor.authorKolber, Adam
dc.date2021-11-25T13:36:30.000
dc.date.accessioned2021-11-26T12:29:36Z
dc.date.available2021-11-26T12:29:36Z
dc.date.issued2015-12-01T07:19:17-08:00
dc.identifierylpr/vol26/iss1/3
dc.identifier.contextkey7886901
dc.identifier.urihttp://hdl.handle.net/20.500.13051/17075
dc.description.abstractPlacebo treatments, like sugar pills and saline injections, are effective in treating pain and perhaps a host of other conditions. In fact, recent neuroimaging studies show that the pathways of placebo pain relief in the brain largely overlap the pathways of pain relief from drugs like morphine.1 Placebos are also cheaper and safer than corresponding active medications. To most effectively use placebos to diagnose and treat patients in clinical practice, however, doctors must deceive patients as to the placebo nature of the intervention. Such deception runs counter to a fifty-year trend in medical ethics and health law that emphasizes patient autonomy and requires doctors to disclose the nature of a proposed intervention in order to obtain patients' informed consent.
dc.titleA Limited Defense of Clinical Placebo Deception
dc.source.journaltitleYale Law & Policy Review
refterms.dateFOA2021-11-26T12:29:37Z
dc.identifier.legacycoverpagehttps://digitalcommons.law.yale.edu/ylpr/vol26/iss1/3
dc.identifier.legacyfulltexthttps://digitalcommons.law.yale.edu/cgi/viewcontent.cgi?article=1548&context=ylpr&unstamped=1


Files in this item

Thumbnail
Name:
04_26YaleL_PolyRev75_2007_2008_.pdf
Size:
3.507Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record